Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in Maryland: - University of Maryland, Baltimore /ID# 259538 — Baltimore, Maryland
- Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476 — Bethesda, Maryland
Phase 3 Recruiting Industry
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…
Sponsor: BeiGene
NCT ID: NCT05100862
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Ascension St Agnes Hospital — Baltimore, Maryland
- American Oncology Partners of Maryland Pa — Bethesda, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Maryland: - American Oncology Partners of Maryland Pa — Bethesda, Maryland
Phase 2, Phase 3 Recruiting Industry
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric a…
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT04442022
Sites in Maryland: - University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Maryland: - American Oncology Partners of Maryland, PA — Bethesda, Maryland
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Maryland: - American Oncology Partners, PA — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Maryland: - Johns Hopkins / Sydney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Sponsor: MeiraGTx, LLC
NCT ID: NCT05926765
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Maryland: - University of Maryland - Marlene and Stewart Greenebaum Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Maryland: - The Center for Cancer and Blood Disorders (CCBD) — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cu…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03922724
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03223610
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other trea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03258567
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05442515
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Sponsor: Carna Biosciences, Inc.
NCT ID: NCT05602363
Sites in Maryland: - University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
Phase 1 Recruiting Industry
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is…
Sponsor: MacroGenics
NCT ID: NCT05362773
Sites in Maryland: - University of Maryland, Greenbaum Comprehensive Cancer Center — Baltimore, Maryland
Phase 1 Recruiting NIH
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nod…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06223542
Sites in Maryland: - National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland